These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 6397984)

  • 41. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin.
    Shimokawa H; Aarhus LL; Vanhoutte PM
    Circ Res; 1987 Aug; 61(2):256-70. PubMed ID: 3113760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of oxyhemoglobin on vasoconstriction in response to 5-hydroxytryptamine in isolated, perfused canine basilar arteries.
    Orz YI; Tsuji T; Aoki T; Yen Y; Chiba S; Kobayashi S
    Neurosurgery; 1998 Nov; 43(5):1176-84. PubMed ID: 9802861
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serotonin and vascular reactivity.
    Van Nueten JM; Janssens WJ; Vanhoutte PM
    Pharmacol Res Commun; 1985 Jul; 17(7):585-608. PubMed ID: 2931729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists.
    Feniuk W; Humphrey PP; Perren MJ; Watts AD
    Br J Pharmacol; 1985 Nov; 86(3):697-704. PubMed ID: 2933110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-HT receptors mediating contractions of the isolated human coronary artery.
    Bax WA; Renzenbrink GJ; Van Heuven-Nolsen D; Thijssen EJ; Bos E; Saxena PR
    Eur J Pharmacol; 1993 Aug; 239(1-3):203-10. PubMed ID: 7693489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
    Robertson JI
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
    McLennan PL; Taylor DA
    Eur J Pharmacol; 1984 Sep; 104(3-4):313-8. PubMed ID: 6499925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries.
    Chester AH; Martin GR; Bodelsson M; Arneklo-Nobin B; Tadjkarimi S; Tornebrandt K; Yacoub MH
    Cardiovasc Res; 1990 Nov; 24(11):932-7. PubMed ID: 2272071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-hydroxytryptamine and vascular disease.
    Vanhoutte PM
    Fed Proc; 1983 Feb; 42(2):233-7. PubMed ID: 6822294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serotonin increases the production of inositol phosphates and mobilises calcium via the 5-HT2 receptor in A7r5 smooth muscle cells.
    Doyle VM; Creba JA; Rüegg UT; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jun; 333(2):98-103. PubMed ID: 2944005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-Hydroxytryptamine and thromboxane A2 in ischaemic heart disease.
    De Clerck F; Janssen PA
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):201-9. PubMed ID: 2130932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries.
    Chester AH; Allen SP; Tadjkarimi S; Yacoub MH
    Circulation; 1993 Mar; 87(3):874-80. PubMed ID: 8443908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Serotoninergic receptors and cardiovascular diseases].
    Hong E; Castillo C; Flores E; Mercedes F
    Gac Med Mex; 1994; 130(3):131-3. PubMed ID: 7657075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-Hydroxytryptamine and the metabolism of arachidonic acid by the lipoxygenase and cyclooxygenase of washed human platelets.
    Dragan YP; Ellis EF
    Biochem Pharmacol; 1990 Jul; 40(2):309-14. PubMed ID: 2142882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet serotonin-LDL interaction in essential hypertension.
    Amstein R; Fetkovska N; Bühler FR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S35-40. PubMed ID: 1717771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.